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The following review has been prepared in collaboration with members of the MRC-NIHR Trials 
Methodology Research Partnership ​1​. The reviewers named above, and other, unnamed 
discussants of the paper, are all qualified statisticians with experience in clinical trials. Our 
objective is to provide a rapid review of publications, preprints and protocols from clinical trials of 
COVID-19 treatments, independent of journal-specific review processes. We aim to provide 
timely, constructive, focused, clear advice aimed at improving both the research outputs under 
review, as well as future studies. Given our collective expertise (clinical trial statistics) our 
reviews focus on the designs of the trials and other statistical content (methods, presentation 
and accuracy of results, inferences). This review reflects the expert opinions of the named 
authors, and does not imply endorsement by the MRC-NIHR Trials Methodology Research 
Partnership, its wider membership, or any other organization.  
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Study Summary 
Here we review ​Chloroquine diphosphate in two different dosages as adjunctive therapy of 
hospitalized patients with severe respiratory syndrome in the context of coronavirus 
(SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb 
clinical trial (CloroCovid-19 Study​ by Borba ​et al​. When we started our review, the report 
presented data collected up to day-6 post-randomization and was posted on MedRxiv here:  
https://www.medrxiv.org/content/10.1101/2020.04.07.20056424v1.full.pdf​. During the process of 
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 our review, the authors updated the preprint to report data up to 13 days post-randomization 
(​https://www.medrxiv.org/content/10.1101/2020.04.07.20056424v2​). 
 
The paper reports an interim analysis of a randomized controlled trial carried out in Manaus, 
Brazil. The trial aimed to recruit 440 adult patients with potential COVID-19 infection based on 
their presentation (but not requiring laboratory confirmation, to avoid any delay in treatment). 
Patients were randomized to receive a low-dose chloroquine regimen (450mg for 5 days, twice 
daily only on the first day, or total dose of 2.7g) or a high-dose regimen (600mg twice daily for 
10 days, or total dose of 12g) using a 1:1 allocation ratio.  
 
Rather than comparing outcomes in the randomized treatment arms to one another, the 
analysis plan was to compare the results from each arm against an expected 20% mortality at 
28 days, following what they observed in a previous patient cohort from Wuhan, China. The 
sample size of 220 per arm (n = 440) was set to provide 80% power to detect a 50% reduction 
in the risk of mortality in either arm. However, after enrollment of 81 patients, the randomization 
of patients to the high-dose arm was halted following the recommendation by the independent 
data safety and monitoring board (DSMB), who cited a greater number of deaths in that arm, as 
well as concerns about cardiotoxicity due to increased QTc and/or ventricular tachycardia.  
 
When we started our review, day-6 mortality was slightly greater in the high-dose arm (7/41 
patients) versus the low-dose arm (4/40 patients). When the updated preprint with day-13 
outcomes was released, 13 of 41 patients in the high-dose arm had died, versus 6/40 patients in 
the low-dose arm. The study will carry on enrolling patients for low-dose chloroquine (as a 
single arm) and will eventually compare the outcome observed in that arm against the 20% 
mortality based on the Wuhan data. 
 
We sincerely thank the authors for their contribution to our collective understanding of 
COVID-19, and for their commitment to the timely dissemination of research results. We also 
appreciate their thoughtful discussion of the limitations of their work - the authors have clearly 
been forthcoming about these. Our detailed review follows. 
 
Major comments 
 
The planned statistical analysis is inconsistent with the typical 
purpose of a randomized controlled trial.  
 
Randomizing patients to a high-dose regimen versus a low-dose regimen would be most 
commonly used to test the safety and efficacy of the two dosing regimens against one another. 
However, the investigators have not planned a direct comparison of the randomized arms, but 
have instead decided to compare the results from each arm (separately) against a “historical 
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 control” derived from two case series of patients from Wuhan where mortality was 20%. 
Effectively, the analysis plan treats the study as two separate “single arm” trials, rather than 
analyzing the data as a two-arm parallel comparative-effectiveness trial. While randomization 
ensures that participant health status or other characteristics do not influence the chloroquine 
dose given, it cannot ensure that the severity of disease in these patients in Manaus, or their 
standard-of-care, was comparable to that of the external control group from Wuhan (more on 
this below). This makes the comparison difficult to interpret. It is unusual to employ 
randomization to create comparable groups and then eschew that entirely in the main analysis.  
 
 
Using  “historical controls” to draw conclusions about efficacy 
creates substantial challenges for interpreting the study’s results.  
 
Following from the above, without a control group of comparable patients receiving therapy 
other than chloroquine, the trial can not provide information about its efficacy versus alternative 
treatment strategies, including standard-of-care. We acknowledge the ethical challenges of a 
placebo-controlled trial in a pandemic situation for a potentially lethal disease, and the authors 
discuss this in their manuscript, noting that “use of placebo in Brazil in severe cases of 
COVID-19 infections is not considered ethically acceptable by national regulatory health 
agencies, especially due to the compassionate use of chloroquine – and because early reports 
seem to indicate its effectiveness ​in vitro​ and ​in vivo​”.  
 
However, it must also be acknowledged that comparisons against a historical control suffer from 
many potential biases.  The use of a historical control may be sufficient in specific settings 
where the disease is well-understood and the treated patients are known to be very similar to 
the historical controls. This is clearly not the case here. Are the patients in the historical control 
group similar to the patients included in this trial with respect to prognostic factors such as age 
and comorbidity? Did clinicians in Manaus have the same understanding of COVID-19 than 
those in Wuhan at the start of the outbreak? Are they receiving other competing therapies that 
could affect their outcomes (patients in this study were also on ceftriaxone and azithromycin)? 
How does the local context, such as potentially overwhelmed intensive care units in some 
regions, affect the mortality rate? The importance of these contextual differences are clearly 
reflected by the variability in COVID-19 mortality rates around the world. Indeed, the two studies 
themselves report different mortality figures (14% and 28%), and while their average is a best 
guess of the true rate, it highlights the difficulties of extrapolating mortality rates from one setting 
to another.  
 
Concurrent controls are thus essential for detecting what are likely to be modest treatment 
effects, and without them we are left with inferences that rest on substantial, untestable 
assumptions. This is why the inclusion of a standard-of-care arm (e.g. a “placebo arm”) is 
ethically sound in circumstances where the effectiveness of a new treatment is unproven and its 
risks are unknown.  
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Recommendations: 
For future studies 
● Ideally, include a randomized comparison of chloroquine against the current 
standard-of-care.  
● Alternatively, if randomizing patients to two chloroquine-based treatment strategies, 
design the trial with planned contrasts of the randomized arms against one another 
rather than comparing each independently against a “historical control”. However, doing 
this without establishing assay sensitivity will still lead to conclusions of limited value.  
For the reader 
● Treat this interim report as very modest evidence of harm from high-dose chloroquine in 
comparison to low-dose chloroquine, and consider other existing data on chloroquine 
and related agents. 
 
 
The authors did not provide enough detail about the decision for early 
stopping. 
 
We at first found it surprising that the DSMB recommended discontinuation of the high-dose arm 
based on the day-6 data (reported April 13th), as well as the authors’ unequivocal conclusion 
that the higher dose was unsafe. However, in the updated preprint (April 17) with data from 
day-13, the mortality figures are more strongly stacked against high-dose arm, and the decision 
makes more sense in that light. The DSMB is, of course, charged with protecting patients and 
may have valid reasons for an abundance of caution. Without any apparent mortality benefit 
(though the study was not designed to demonstrate such benefits at this stage of enrollment), 
the observed difference in deaths, along with the early hints of cardiotoxicity (two patients with 
ventricular tachycardia in the high-dose arm), were clearly enough for the DSMB to suggest 
action. However, the DSMB’s decision-making process is barely mentioned in the preprint, 
which only says that DSMB recommended halting randomization due to concerns about safety 
in the high-dose arm. It would be helpful if the authors could further report what exact data the 
DSMB had access to when the trial was stopped, along with any other pertinent details. While 
we appreciate the importance of promptly disseminating results, new and ongoing studies will 
use these earlier study reports as guidance. This reinforces the importance of communicating 
exactly how and why decisions were made. We thus encourage the study team to include more 
details about what information was used to base the decision on, and/or the DSMB to write its 
own explanation for the recommendation.  
 
Finally, given that the study stopped based on a relatively small number of events without 
“statistically significant” evidence of harm, it is worth noting that the high-dose arm included 
more elderly patients, more high-risk patients (defined by qSOFA >= 2) and more patients with 
heart disease.  Ordinarily we advise against consideration of baseline balance in randomized 
trials because the standard errors, when properly calculated, make an allowance for any 
random differences between the groups.  However, when the evidence to conclude harm was 
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 based on so few events, and formal statistical analysis provides minimal or weak evidence of 
“harm” - it may be worth asking if that small number of events could be driven by the small 
surplus of patients with heart problems in the high-dose arm, given that the small number of 
cardiotoxicity events was the likely reason for stopping. 
 
Recommendations: 
For future studies 
● Clear report the rationale for any changes made during the course of the trial, whether 
due to a recommendation from the DSMB, or any other reason.  
For this study 
● Provide more detailed rationale for the DSMB’s decision to halt enrollment into the 
high-dose arm 
 
Minor points 
- Even though the stated aim of the paper was ​to comprehensively evaluate the safety and 
efficacy of two different chloroquine doses in patients with established severe COVID-19, the 
authors weren’t able to confirm patients’ COVID-19 diagnosis until after they were randomized 
(due to delays in testing). For that reason, even though 81 patients were enrolled in the trial, 
only 62 had confirmed COVID-19.  The argument for including participants ahead of formal 
diagnosis is well justified and reflective of “real world” clinical practice (e.g. treatment may need 
to be started before infection can be confirmed by lab testing) but it may impact the 
generalizability of the results to COVID-19 patients.  The title and abstract could be modified to 
say “with suspected coronavirus…” to make it more clear that not all enrolled patients had 
“established” COVID-19. 
 
- ​The authors presented p-values in Table 1 comparing the baseline characteristics of the 
randomized treatment arms. This practice goes against expert guidance, as explained in the 
CONSORT explanation and elaboration document 
(​http://www.consort-statement.org/checklists/view/32--consort-2010/510-baseline-data​). Even in 
cases like this one where early stopping is based on very small number of events, and there 
may be a need to carefully examine the “balance” of important prognostic factors at baseline 
(e.g. noting that the 5 patients in the high-dose arm were over 75 years versus 0 in the low-dose 
arm, or that 5 patients in the high-dose arm had heart disease versus 0 in the low-dose arm) 
this wouldn’t be based on the reported p-values.  
 
- There were several other inconsistencies in the reporting, obscuring exactly what was done. In 
some places, p-values are presented but the tests that led to those p-values are not clear. The 
methods note that, “For qualitative variables, Chi-square tests and  Fisher's exact test were 
performed”, but this is not specific enough to understand what was done for each outcome. The 
reader should not have to guess this information. Further, several outcomes presented under 
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 methods were not analysed for the publication, although in some cases that is due to the 
ongoing nature of the study (e.g. day 28 follow-up). It is also unclear whether any participants 
recovered or were censored for a different reason during the analysed follow-up. 
 
- ​There were outcomes noted in the April 13th version of the pre-print that are missing entirely 
from the April 17th update. Further, the April 13 preprint included a Table with some adverse 
events that were incompletely reported, adding confusion regarding the overall outcomes. This 
has been corrected in the update posted on April 17th, but we note it here for completeness.  
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 CONSORT CHECKLIST 
To support the review, we completed the CONSORT checklist​ ​10​ below. Material taken directly 
from the paper (or trial registry) is in ​italics. ​Our additional comments are in ​bold​.  
Title and abstract 
1a Identification as a randomised trial in the title: ​Yes 
1b Structured summary of trial design, methods, results, and conclusions. 
Title: Identification of the study as randomised Yes 
Authors: Contact details for the corresponding author No 
Trial design: Description of the trial design (eg, parallel, cluster, non-inferiority) Yes 
Methods  
Participants: Eligibility criteria for participants and the settings where the data were collected Yes 
Interventions: Interventions intended for each group Yes 
Objective: Specific objective or hypothesis Yes 
Outcome: Clearly defined primary outcome for this report Yes 
Randomisation: How participants were allocated to interventions Yes 
Blinding (masking): Whether or not participants, care givers, and those assessing the outcomes were 
blinded to group assignment 
Yes 
Results  
Numbers randomised: Number of participants randomised to each group Yes 
Recruitment: Trial status Yes 
Numbers analysed: Number of participants analysed in each group Yes 
Outcome: For the primary outcome, a result for each group and the estimated effect size and its precision Sort of? 
Harms: Important adverse events or side-effects Yes, but poorly 
Conclusions: General interpretation of the results Yes 
Trial registration: Registration number and name of trial register Yes 
Funding: Source of funding Yes 
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 Introduction 
Background and objectives 
2a Scientific background and explanation of rationale: ​Present 
2b Specific objectives or hypotheses: ​Present 
Methods 
Trial design 
3a Description of trial design (such as parallel, factorial) including allocation ratio: 
Present 
3b Important changes to methods after trial commencement (such as eligibility criteria), 
with reasons: ​Present 
Participants 
4a Eligibility criteria for participants: ​Present 
4b Settings and locations where the data were collected: ​Present 
Interventions 
5 The interventions for each group with sufficient details to allow replication, including 
how and when they were actually administered: ​Present 
Outcomes 
6a Completely defined pre-specified primary and secondary outcome measures, 
including how and when they were assessed: ​Present 
6b Any changes to trial outcomes after the trial commenced, with reasons: ​Present, but 
secondary outcomes seem inconsistent with trial registration; could be related to 
early stopping? 
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 Sample size 
7a How sample size was determined: ​Present, but poorly done (see review) 
7b When applicable, explanation of any interim analyses and stopping guidelines: 
Minimal description despite trial stopping early 
Randomisation 
Sequence generation 
8a Method used to generate the random allocation sequence: ​Present 
8b Type of randomisation; details of any restriction (such as blocking and block size): 
Present 
Allocation concealment mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially 
numbered containers), describing any steps taken to conceal the sequence until 
interventions were assigned: ​Present (not ideally done - sealed envelopes - but it is 
reported) 
Implementation 
10 Who generated the random allocation sequence, who enrolled participants, and who 
assigned participants to interventions: ​Present  
Blinding 
11a If done, who was blinded after assignment to interventions (for example, 
participants, care providers, those assessing outcomes) and how: ​Present  
11b If relevant, description of the similarity of interventions: ​Present  
Statistical methods 
12a Statistical methods used to compare groups for primary and secondary outcomes: 
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 Poorly reported 
12b Methods for additional analyses, such as subgroup analyses and adjusted 
analyses: ​Poorly reported 
Results 
Participant flow (a diagram is strongly recommended) 
13a For each group, the numbers of participants who were randomly assigned, received 
intended treatment, and were analysed for the primary outcome: ​Present 
13b For each group, losses and exclusions after randomisation, together with reasons: 
Poorly reported 
Recruitment 
14a Dates defining the periods of recruitment and follow-up: ​Present 
14b Why the trial ended or was stopped: ​Present, but would like more details about 
DSMB decision 
Baseline data 
15 A table showing baseline demographic and clinical characteristics for each group: 
Present 
Numbers analysed 
16 For each group, number of participants (denominator) included in each analysis and 
whether the analysis was by original assigned groups: ​Present 
Outcomes and estimation 
17a For each primary and secondary outcome, results for each group, and the 
estimated effect size and its precision (such as 95% confidence interval): ​Present, but 
oddly displayed (tied to odd analysis plan - a randomized trial that doesn’t plan to 
compare the randomized groups for a primary outcome of mortality, but then 
stops early due to safety concerns based on comparing the randomized groups) 
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 17b For binary outcomes, presentation of both absolute and relative effect sizes is 
recommended 
Ancillary analyses 
18 Results of any other analyses performed, including subgroup analyses and adjusted 
analyses, distinguishing pre-specified from exploratory: ​Present, but oddly displayed 
(see review) 
Harms 
19 All important harms or unintended effects in each group (for specific guidance see 
CONSORT for harms42): ​Present, but oddly displayed (see review) 
Discussion 
Limitations 
20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, 
multiplicity of analyses:​ Fairly good 
Generalisability 
21 Generalisability (external validity, applicability) of the trial findings: ​Present 
Interpretation 
22 Interpretation consistent with results, balancing benefits and harms, and considering 
other relevant evidence:​ okay for most part, but surprising how strongly they 
recommend against high-dose chloroquine given that these data are fairly weak 
Other information 
Registration 
23 Registration number and name of trial registry: ​Present 
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 Protocol 
24 Where the full trial protocol can be accessed, if available: ​Present 
Funding 
25 Sources of funding and other support (such as supply of drugs), role of funders: 
Present 
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